Objectives: Our aim was to predict progression of non-muscle-invasive bladder urothelial
carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality
of tumors with a new UroVysion scoring system.Methods: Seventy-five bladder cancer
cases (including 57 NMIUCs) were classified according to the quantitatively assessed
degree of UroVysion-detected chromosomal abnormalities into urine fluorescence in
situ hybridization score (UFS) groups: UFS I, II, and III. Cox time-to-event, Kaplan-Meier,
and C-statistics analyses were performed.Results: UFS proved to be an independent
prognostic factor of progression-free survival (PFS) and time to progression (TTP).
NMIUCs with UFS III had a 34.05-fold increased hazard for progression to muscle-invasive
cancer (TTP; 95% confidence interval, 5.841-198.5; P < .001) in comparison with UFS
I to II cases. The addition of UFS to conventional risk scores increased the C-index
for PFS and TTP.Conclusions: UFS can indicate an increased risk for progression into
muscle-invasive disease in patients with NMIUC and improves prognostic accuracy of
the current clinical risk assessment systems.
